AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7836964 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 healthy volunteers)
Number of subjects: 41
Study 3354865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride 0.2 mg/kg
Number of subjects: 20
Study 3354865 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 20
Study 31688884 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 517
Study 31688884 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 517
Study 28872484 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 492
Study 28872484 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 492
Study 28872484 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 492
Study 28872484 — intervention group
Group type: COMPARATOR
Intervention: Xenon vs Sevoflurane
Number of subjects: 492
Study 26599904 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg tablet, three times per day)
Number of subjects: 128
Study 21853340 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parenting programme
Number of subjects: 0
Study 21853340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of the Incredible Years programme
Number of subjects: 0
Study 21216384 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced frequency Lissajous feedback
Number of subjects: 0
Study 21216384 — intervention group
Group type: COMPARATOR
Intervention: Lissajous feedback (standard frequency)
Number of subjects: 0
Study 18485269 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper questionnaire using numerical rating scales
Number of subjects: 200
Study 18485269 — intervention group
Group type: COMPARATOR
Intervention: Electronic questionnaire using visual analogue scales (with or without a numerical indicator)
Number of subjects: 200
Study 22525343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 24
Study 15671570 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at 0.125 gm/m2
Number of subjects: 0
Study 15671570 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at 0.5 gm/m2
Number of subjects: 0
Study 15671570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12858462 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micro g of teriparatide by daily self-injection
Number of subjects: 365
Study 12858462 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micro g of teriparatide by daily self-injection
Number of subjects: 365
Study 12858462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 10206803 — intervention group
Group type: EXPERIMENTAL
Intervention: Perflenapent (EchoGen)
Number of subjects: 13
Study 7753338 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) infusion (1 microgram/kg/h) with metyrapone
Number of subjects: 6
Study 7753338 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study 7753338 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone alone
Number of subjects: 6
Study 2276652 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 30
Study 2276652 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 30
Study 7004845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 138
Study 7004845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study 30184222 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary food supplements (CFSs)
Number of subjects: 25
Study 30184222 — intervention group
Group type: COMPARATOR
Intervention: Control (child-feeding counseling for mothers)
Number of subjects: 25
Study 27297847 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliminating patient copayment for P2Y12 receptor inhibitor therapy
Number of subjects: 11000
Study 27297847 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard copayment)
Number of subjects: 11000
Study 24685421 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of treatment by a homeopath
Number of subjects: 162
Study 24685421 — intervention group
Group type: COMPARATOR
Intervention: No Offer
Number of subjects: 162
Study 24685421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 162
Study 22425028 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple vendor-operated wireless POS terminals for 9 months (June 2008-February 2009)
Number of subjects: 0
Study 22425028 — intervention group
Group type: COMPARATOR
Intervention: Single market-operated terminal
Number of subjects: 0
Study 20056802 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 21
Study 20056802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18566455 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS visual acuity measurements
Number of subjects: 107
Study 18566455 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS visual acuity measurements (revised)
Number of subjects: 107
Study 18566455 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at week 1 visit
Number of subjects: 107
Study 17108494 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL based rehabilitation (ABR) for 2 weeks
Number of subjects: 13
Study 17108494 — intervention group
Group type: COMPARATOR
Intervention: Exercise based rehabilitation (EBR) for 4 weeks
Number of subjects: 13
Study 14685447 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from a multiprofessional breastfeeding team (G1)
Number of subjects: 101
Study 14685447 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from a pediatrician trained in breastfeeding (G2)
Number of subjects: 101
Study 14685447 — intervention group
Group type: COMPARATOR
Intervention: Advice from a pediatrician with no breastfeeding training (G3)
Number of subjects: 101
Study 14685447 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a pacifier
Number of subjects: 101
Study 14685447 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal schooling
Number of subjects: 101
Study 11076105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis vintage
Number of subjects: 310
Study 11076105 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium, phosphorus, and vintage (as predictors)
Number of subjects: 310
Study 8980935 — intervention group
Group type: EXPERIMENTAL
Intervention: RAT2 (ranitidine 300 mg twice daily, amoxycillin 1000 mg twice daily, plus tinidazole 500 mg twice daily for 2 weeks)
Number of subjects: 232
Study 8980935 — intervention group
Group type: COMPARATOR
Intervention: RA2 (ranitidine 300 mg twice daily plus amoxycillin 1000 mg twice daily for 2 weeks)
Number of subjects: 232
Study 1727754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube-fed nutrition (1.5 g/kg protein and 167 kJ/kg daily)
Number of subjects: 31
Study 1727754 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (control)
Number of subjects: 31
Study 6748919 — intervention group
Group type: EXPERIMENTAL
Intervention: TMJ repositioning with a splint that optimized jaw position
Number of subjects: 11
Study 6748919 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo splint with no occlusal contact
Number of subjects: 11
Study 6748919 — intervention group
Group type: COMPARATOR
Intervention: Normal condition (without a bite splint)
Number of subjects: 11
Study 6748919 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint that magnified the subjects normal degree of malocclusion
Number of subjects: 11
Study 29976087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 12
Study 29976087 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide
Number of subjects: 12
Study 29976087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29246659 — intervention group
Group type: EXPERIMENTAL
Intervention: AND exposure
Number of subjects: 80
Study 29246659 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 80
Study 25967526 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% preserved with SofZia (TRAVATAN Z solution)
Number of subjects: 56
Study 25967526 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride‐preserved latanoprost 0.005% (XALATAN)
Number of subjects: 56
Study 25303370 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with gastric tissue expressing IL-22
Number of subjects: 68
Study 25303370 — intervention group
Group type: COMPARATOR
Intervention: Patients without gastric tissue expressing IL-22
Number of subjects: 68
Study 21987393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (immediate-treatment group)
Number of subjects: 155
Study 21987393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (delayed-treatment group)
Number of subjects: 155
Study 20022188 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise training for 6 months
Number of subjects: 332
Study 20022188 — intervention group
Group type: COMPARATOR
Intervention: Quartile 1 (referent group)
Number of subjects: 332
Study 20022188 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 2
Number of subjects: 332
Study 20022188 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 3
Number of subjects: 332
Study 20022188 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4
Number of subjects: 332
Study 17873022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at a rate of 5 pmol/kg per minute for 180 min
Number of subjects: 15
Study 17873022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 15
Study 16119352 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal+masker trials
Number of subjects: 12
Study 16119352 — intervention group
Group type: COMPARATOR
Intervention: Signal-alone trials
Number of subjects: 12
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained hypertension
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline hypertension
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensive
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical stroke and myocardial infarction
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes, uricaemia, and high heart rate
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse blood pressure and murmurs at the neck
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical heart failure, proteinuria, and tachycardia
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Historical stroke and myocardial infarction, pulmonary disease, left ventricular hypertrophy, diabetes, and uricaemia
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3282
Study 11840226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia
Number of subjects: 3282
Study 10512130 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (60 mg/m2) given as a 3‐h infusion on days 1, 8, 15, 22, 29 and 36; CHART started on day 15 with 150 cGy/fraction given three times a day for a total dose of 54 Gy in 12 days.
Number of subjects: 20
Study 10512130 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and CHART regimen
Number of subjects: 20
Study 7555483 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable implantable pump therapy
Number of subjects: 224
Study 2252119 — intervention group
Group type: EXPERIMENTAL
Intervention: Open diagnostic peritoneal lavage
Number of subjects: 242
Study 2252119 — intervention group
Group type: COMPARATOR
Intervention: Closed diagnostic peritoneal lavage
Number of subjects: 242
Study 6113885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium bromide 1 mg . kg‐1
Number of subjects: 50
Study 6113885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium bromide 1.5 mg . kg‐1
Number of subjects: 50
Study 6113885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium bromide
Number of subjects: 50
Study 31028768 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary selective laser trabeculoplasty (SLT)
Number of subjects: 355
Study 31028768 — intervention group
Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 355
Study 30243214 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour instructor-led ICF training
Number of subjects: 76
Study 30243214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 26808988 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial (LA) enlargement in female AF patients
Number of subjects: 2615
Study 26808988 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial (LA) diameter
Number of subjects: 2615
Study 24477763 — intervention group
Group type: EXPERIMENTAL
Intervention: no-stop signal bias
Number of subjects: 18
Study 24477763 — intervention group
Group type: EXPERIMENTAL
Intervention: stop-signal bias
Number of subjects: 18
Study 24477763 — intervention group
Group type: COMPARATOR
Intervention: no-stop trials
Number of subjects: 18
Study 23176536 — intervention group
Group type: EXPERIMENTAL
Intervention: E-ADL-Test
Number of subjects: 139
Study 20236365 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine (36 g tid on 10 consecutive days per month; n=10)
Number of subjects: 45
Study 20236365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg nocte; n=12)
Number of subjects: 45
Study 20236365 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine plus Pravastatin (n=11)
Number of subjects: 45
Study 20236365 — intervention group
Group type: COMPARATOR
Intervention: Neither (Control group; n=12)
Number of subjects: 45
Study 17401044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg dexamethasone suppression test
Number of subjects: 32
Study 17401044 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 32
Study 15707766 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (BD)
Number of subjects: 40
Study 15707766 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day (BD)
Number of subjects: 40
Study 12123331 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIFAFU (Irinotecan 200 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 850 mg/m2)
Number of subjects: 234
Study 12123331 — intervention group
Group type: COMPARATOR
Intervention: MTXFAFU (Methotrexate 750 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 800 mg/m2)
Number of subjects: 234
Study 12123331 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIFAFU
Number of subjects: 234
Study 12123331 — intervention group
Group type: COMPARATOR
Intervention: MTXFAFU
Number of subjects: 234
Study 10407253 — intervention group
Group type: COMPARATOR
Intervention: Immunostimulant
Number of subjects: 0
Study 10407253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions of plasma rich in anti-HIV1
Number of subjects: 0
Study 8569016 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 596
Study 8569016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 8569016 — intervention group
Group type: EXPERIMENTAL
Intervention: E+P regimens (0.625 mg/d of CEE plus 10 mg/d of MPA for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of MP for the first 12 days)
Number of subjects: 596
Study 8569016 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of CEE
Number of subjects: 596
Study 8569016 — intervention group
Group type: EXPERIMENTAL
Intervention: E+P regimens
Number of subjects: 596
Study 2013416 — intervention group
Group type: EXPERIMENTAL
Intervention: Big gulps
Number of subjects: 14
Study 2013416 — intervention group
Group type: COMPARATOR
Intervention: Little swallows
Number of subjects: 14
Study 2013416 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet swallows (patients)
Number of subjects: 14
Study 6122852 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% phenoxetol and 0.2% chlorhexidine cream
Number of subjects: 0
Study 6122852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30014302 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 42
Study 30014302 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 42
Study 26375410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet (D)
Number of subjects: 0
Study 26375410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet combined with supervised exercise training (D + E)
Number of subjects: 0
Study 25481936 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start AET program
Number of subjects: 200
Study 25481936 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 200
Study 25481936 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start AET protocol (TR)
Number of subjects: 200
Study 22403594 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional training unit (conducting anamnesis and clinical examination) before OSCE
Number of subjects: 0
Study 22403594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 0
Study 22403594 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 19382041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 0
Study 19382041 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 0
Study 17559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg once-daily
Number of subjects: 555
Study 17559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once-daily
Number of subjects: 555
Study 17559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once-daily
Number of subjects: 555
Study 17559733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice-daily
Number of subjects: 555
Study 17559733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 16354865 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP)
Number of subjects: 290
Study 16354865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DMP)
Number of subjects: 290
Study 16354865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of patients residing in an institution
Number of subjects: 290
Study 16354865 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers overall
Number of subjects: 290
Study 11778705 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20
Study 11778705 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 20
Study 11207490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micrograms
Number of subjects: 60
Study 11207490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous syntocinon 10 IU
Number of subjects: 60
Study 9766535 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 70
Study 9766535 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 7828614 — intervention group
Group type: EXPERIMENTAL
Intervention: PET (FDG)
Number of subjects: 45
Study 7828614 — intervention group
Group type: EXPERIMENTAL
Intervention: SPET (HMPAO)
Number of subjects: 45
Study 3396568 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat, high protein diet (FP)
Number of subjects: 5
Study 3396568 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO)
Number of subjects: 5
Study 8042809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (360 micrograms)
Number of subjects: 42
Study 8042809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (72 micrograms)
Number of subjects: 42
Study 8042809 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 42
Study 8042809 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol and ipratropium bromide
Number of subjects: 42
Study 8042809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator treatment
Number of subjects: 42
Study 715126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhabituation exposure conditions (60, 120, or 180 trials) with standard stimulus (SS)
Number of subjects: 108
Study 715126 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulus intensities (60 or 85 dB)
Number of subjects: 108
Study 715126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group defined by numerous overhabituation responses
Number of subjects: 108
Study 715126 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of overhabituation
Number of subjects: 108
Study 30591006 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142
Study 30591006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 29879285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal hump reduction simulation
Number of subjects: 813
Study 29879285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined simulation of dorsum and tip rotation
Number of subjects: 813
Study 29879285 — intervention group
Group type: COMPARATOR
Intervention: Tip rotation alone
Number of subjects: 813
Study 27775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isostearamidopropyl morpholine lactate (0.5% and 1.0% aq)
Number of subjects: 47
Study 27775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleamidopropyl dimethylamine
Number of subjects: 47
Study 27775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylaminopropylamine
Number of subjects: 47
Study 27775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocamide diethanolamine (DEA)
Number of subjects: 47
Study 27775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-reactivity among surfactants
Number of subjects: 47